Harmony Biosciences Holdings (HRMY) said Monday it expects Q4 net product revenue of $201 million.
Analysts polled by FactSet expect $198.6 million.
The company reported preliminary 2024 net product revenue for the year ended Dec. 31 of $714 million, falling within its guidance for $700 million to $720 million.
Analysts surveyed by FactSet expect $712.1 million.
Harmony said it expects 2025 net product revenue of between $820 and $860 million. Analysts polled by FactSet expect $847.3 million.
Shares of the company were up more than 6% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.